Industry
Manufacturers of agents for neuroblastoma
| AGENT | COMPANY | NOTES |
| I-131 MIBG,
I-131 iobenguane |
DRAXIMAGE Montreal, ON |
a division of DRAXIS Specialty Pharmaceuticals Inc. is now Jubilant DraxImage Inc. Acquired by Jubilant Life Sciences (Indian pharmaceutical company) in May 2008. Jubilant website: http://www.jubl.com/ |
| I-123 MIBG,
I-123 iobenguane, |
GE Healthcare | FDA-approved I 123 mIBG for the imaging of neuroendocrine tumors in 2008; |
| Azedra™ (Ultratrace™ Iobenguane I 131 or Ultratrace MIBG) | Molecular Insight
Cambridge, MA |
orphan drug status 2006 Molecular Insight faces Chapter 11 Jan 2011
|
| Seneca Valley virus SVV-001, NTX-010 | Neotropix | Currently in phase I in pediatric solid tumors and phase II lung cancer |
| Vaccinia virus, JX-594 | Jennerex Biotherapeutics
San Francisco, CA |
Currently in phase I in pediatric solid tumors and phase I and II adult trials for solid tumors |
| REOLYSIN (reovirus) | Oncolytics Biotech Inc. Calgary, AB | Phase I ped study announced |
| MNX-100 (nifurtimox) | MetronomX, Singapore
(Houston, TX headquarters) |
Formed in 2010, plans to obtain FDA orphan drug status and file for EMEA approval |
| KRX-0401, (perifosine) | Aeterna Zentaris Inc (Quebec) and Keryx Biopharmaceuticals Inc (New York) | FDA granted orphan drug status for treatment of NB July 2010 |
| ch14.18 | United Therapeutics, Silver Spring, Maryland | Agreement with NCI July 2010 to file FDA approval |
| 8H9 | United Therapeutics, Silver Spring, Maryland | License agreement with MSKCC Dec 2007 |
| ch14.18/CHO | Apeiron Biologics, Vienna Austria | Acquired rights to ch14.18/CHO for use in SIOPEN trial in Europe Jun 2011 |
| hu14.18-IL2 | Apeiron Biologics, Vienna Austria | Acquired rights to hu14.18-IL2 Feb 2011; plans for international trials in US and Europe |
